Personensuche
Personensuche
Es wurde 1 Person gefunden.
WiWi / IBES
Anschrift
Weststadttürme, Berliner Platz 6-8
45127 Essen
45127 Essen
Raum
WST-B.09.04
Telefon
Webseite
Funktionen
-
Juniorprofessor/in, Juniorprofessur für empirische Gesundheitsökonomik
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Availability of New Medicines in the US and Germany From 2004 to 2018In: JAMA Network Open Jg. 5 (2022) Nr. 8,ISSN: 2574-3805Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? : A Retrospective Analysis of Switzerland 2015-2020In: Value in Health Jg. 25 (2022) Nr. 7, S. 1124 - 1132ISSN: 1524-4733; 1098-3015Online Volltext: dx.doi.org/ (Open Access)
-
The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in GermanyIn: Value in Health Jg. 25 (2022) Nr. 9, S. 1528 - 1538ISSN: 1524-4733; 1098-3015Online Volltext: dx.doi.org/
-
Do soft cost-control measures change productivity? : Preferred statin prescribing in Germany
81st Annual Meeting of the Academy of Management 2021: Bringing the Manager Back in Management, 29.07.-04.08.2021, Virtual,In: Academy of Management Proceedings (2021)ISSN: 0065-0668; 2151-6561Online Volltext: dx.doi.org/ -
Regional innovation systems of medical technology : A knowledge production function of cardiovascular research and funding in europeIn: REGION: The Journal of ERSA Jg. 8 (2021) Nr. 2, S. 57 - 81ISSN: 2409-5370Online Volltext: dx.doi.org/ (Open Access)
-
Are patients more adherent to newer drugs?In: Health Care Management Science Jg. 23 (2020) Nr. 4, S. 605 - 618ISSN: 1572-9389; 1386-9620Online Volltext: dx.doi.org/ (Open Access)
-
Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in GermanyIn: International Journal of Environmental Research and Public Health = IJERPH Jg. 17 (2020) Nr. 11, S. 4113ISSN: 1660-4601; 1661-7827Online Volltext: dx.doi.org/ (Open Access)
-
The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in GermanyIn: Health Economics Jg. 29 (2020) Nr. S1, S. 63 - 82ISSN: 1099-1050; 1057-9230Online Volltext: dx.doi.org/ (Open Access)
-
Ambulant-sensitive Krankenhausfälle in Deutschland : Abgrenzung, Prävalenz und KostenIn: Gesundheitsökonomie & Qualitätsmanagement Jg. 24 (2019) Nr. 6, S. 277 - 291ISSN: 1439-4049; 1432-2625Online Volltext: dx.doi.org/
-
Improving Service Provision : The Health Care Services’PerspectiveIn: Journal of Service Management Research Jg. 3 (2019) Nr. 4, S. 163 - 183ISSN: 2511-8676Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Service quality and perceived customer value in community pharmaciesIn: Health Services Management Research Jg. 23 (2019) Nr. 1, S. 36 - 48ISSN: 1758-1044; 0951-4848Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Stakeholder Participation in Regulatory Decision-MakingIn: Academy of Management Proceedings Jg. 2018 (2018) Nr. 1, S. 11748ISSN: 0065-0668; 2151-6561Online Volltext: dx.doi.org/
-
The impact of physician-level drug budgets on prescribing behaviorIn: The European Journal of Health Economics Jg. 19 (2018) Nr. 2, S. 213 - 222ISSN: 1618-7601; 1618-7598Online Volltext: dx.doi.org/
-
Dispensing behaviour of pharmacies in prescription drug marketsIn: Health policy: education, health service delivery and regulation Jg. 120 (2016) Nr. 2, S. 190 - 197ISSN: 0168-8510; 1872-6054Online Volltext: dx.doi.org/
-
Drug safety and the impact of drug warnings : An interrupted time series analysis of diabetes drug prescriptions in Germany and DenmarkIn: Health Policy Jg. 120 (2016) Nr. 12, S. 1404 - 1411ISSN: 0168-8510; 1872-6054Online Volltext: dx.doi.org/
-
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and AustraliaIn: Health policy Jg. 120 (2016) Nr. 10, S. 1115 - 1122ISSN: 0168-8510; 0168-8510Online Volltext: dx.doi.org/ (Open Access)
-
The diffusion of generics after patent expiry in GermanyIn: The European Journal of Health Economics Jg. 17 (2016) Nr. 8, S. 1027 - 1040ISSN: 1618-7601; 1618-7598Online Volltext: dx.doi.org/
-
Early benefit assessment of pharmaceuticals in Germany: Manufacturers' expectations versus the Federal Joint Committee's decisionsIn: Medical decision making (MDM) Jg. 34 (2014) Nr. 8, S. 1030 - 1047ISSN: 1552-681X; 0272-989XOnline Volltext: dx.doi.org/
-
Funding decisions for newborn screening: A comparative review of 22 decision processes in EuropeIn: International Journal of Environmental Research and Public Health = IJERPH Jg. 11 (2014) Nr. 5, S. 5403 - 5430ISSN: 1660-4601; 1661-7827Online Volltext: dx.doi.org/ (Open Access)
-
Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten LändernIn: Recht und Politik im Gesundheitswesen: RPG Jg. 19 (2013) Nr. 3, S. 67 - 81ISSN: 0948-3209
-
Link between process and appraisal in coverage decisions: An analysis with structural equation modelingIn: Medical decision making (MDM) Jg. 33 (2013) Nr. 8, S. 1009 - 1025ISSN: 1552-681X; 0272-989XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Transparency vs. closed-door policy : Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysisIn: Health Policy Jg. 112 (2013) Nr. 3, S. 187 - 196ISSN: 0168-8510; 1872-6054Online Volltext: dx.doi.org/
-
A systematic review of coverage decision-making on health technologies : Evidence from the real worldIn: Health Policy Jg. 107 (2012) Nr. 2-3, S. 218 - 230ISSN: 0168-8510; 1872-6054Online Volltext: dx.doi.org/
-
Decision-making in healthcare: A practical application of partial least square path modelling to coverage of newborn screening programmesIn: BMC Medical Informatics and Decision Making Jg. 12 (2012) Nr. 1,ISSN: 1472-6947Online Volltext: dx.doi.org/ (Open Access)
-
A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and preventionIn: Health Policy Jg. 101 (2011) Nr. 3, S. 290 - 299ISSN: 0168-8510; 1872-6054Online Volltext: dx.doi.org/
-
The role of health technology assessment in coverage decisions on newborn screeningIn: International Journal of Technology Assessment in Health Care Jg. 27 (2011) Nr. 4, S. 313 - 321ISSN: 0266-4623; 1471-6348Online Volltext: dx.doi.org/
-
Analysing coverage decision-making : Opening Pandora’s box?In: The European Journal of Health Economics Jg. 15 (2014) Nr. 9, S. 899 - 906ISSN: 1618-7601; 1618-7598Online Volltext: dx.doi.org/
-
Information on product quality, change agency and product adoptionIn: Academy of Management Proceedings Jg. 2017 (2017) Nr. 1, S. 13580ISSN: 0065-0668; 2151-6561Online Volltext: dx.doi.org/
-
A concise guide to reproducible research using secondary data(2022)Online Volltext; Online Volltext (Open Access)
-
A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations : Evidence from Preferred Drug Policies in Germany(2021)
(CINCH working paper series ; 2021/08)Online Volltext: dx.doi.org/ Online Volltext (Open Access)